Amneal rated Buy in new research coverage at UBS as growth pipeline expands (AMRX:NASDAQ)
Summary
UBS starts Amneal Pharma (AMRX) at Buy with $19 target, citing strong growth in Parkinson’s drugs, generics pipeline, and margin upside—read more.
Description
UBS starts Amneal Pharma (AMRX) at Buy with $19 target, citing strong growth in Parkinson’s drugs, generics pipeline, and margin upside—read more.
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source